Is MIST or MLYS more undervalued in 2026?

CirclFi compares Milestone Pharmaceuticals Inc. (MIST) and Mineralys Therapeutics, Inc. (MLYS) using 13 institutional-grade valuation models. MIST has a Quality of Company score of 3.6/10 while MLYS scores 4.3/10.

Which is a better buy — MIST or MLYS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MIST and MLYS valuations compare?

MIST at $1.44 and MLYS at $31.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MIST vs MLYS Valuation Comparison 2026 — Intrinsic Value Analysis

MIST

Biotechnology

Milestone Pharmaceuticals Inc.

Quality

3.6

out of 10

Value Trap

LOW

Price

$1.44

Last close

Models

7/13

Active

MLYS

Biotechnology

Mineralys Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$31.54

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	MIST Fair Value	MIST Upside	MLYS Fair Value	MLYS Upside
Bayesian DCF	Intrinsic	$0.50	-65.3%	$10.20	-67.6%
Earnings Power Value	Intrinsic	—	—	$14.31	-48.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.23	-83.7%	$6.22	-80.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MIST vs MLYS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MIST vs MLYS — Which Stock Is More Undervalued?

MLYS scores higher with a 4.3/10 quality rating vs MIST's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Milestone Pharmaceuticals Inc. (MIST) and Mineralys Therapeutics, Inc. (MLYS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MIST currently trades at $1.44 with a QOC of 3.6/10, while MLYS trades at $31.54 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).